home / stock / crbu / crbu quote
Last: | $3.73 |
---|---|
Change Percent: | -1.31% |
Open: | $3.88 |
Close: | $3.73 |
High: | $3.89 |
Low: | $3.685 |
Volume: | 1,233,857 |
Last Trade Date Time: | 05/07/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.73 | $3.88 | $3.73 | $3.89 | $3.685 | 1,233,857 | 05-07-2024 |
$3.83 | $3.85 | $3.83 | $3.93 | $3.76 | 1,571,752 | 05-06-2024 |
$3.77 | $3.77 | $3.77 | $3.9 | $3.69 | 1,817,389 | 05-03-2024 |
$3.64 | $3.75 | $3.64 | $3.82 | $3.56 | 2,348,641 | 05-02-2024 |
$3.69 | $3.65 | $3.69 | $3.85 | $3.61 | 1,739,878 | 05-01-2024 |
$3.63 | $3.76 | $3.63 | $3.76 | $3.61 | 1,473,220 | 04-30-2024 |
$3.78 | $3.74 | $3.78 | $3.895 | $3.71 | 1,476,646 | 04-29-2024 |
$3.71 | $3.9 | $3.71 | $3.9 | $3.69 | 1,044,964 | 04-26-2024 |
$3.76 | $3.8 | $3.76 | $3.84 | $3.71 | 1,632,852 | 04-25-2024 |
$3.85 | $4 | $3.85 | $4.04 | $3.8 | 955,214 | 04-24-2024 |
$3.98 | $4 | $3.98 | $4.21 | $3.98 | 926,550 | 04-23-2024 |
$3.99 | $3.89 | $3.99 | $4.075 | $3.8 | 1,384,845 | 04-22-2024 |
$3.85 | $3.9 | $3.85 | $4.03 | $3.78 | 1,713,612 | 04-19-2024 |
$3.91 | $3.88 | $3.91 | $4.015 | $3.875 | 1,415,632 | 04-18-2024 |
$3.91 | $4.05 | $3.91 | $4.09 | $3.85 | 1,998,823 | 04-17-2024 |
$4.01 | $4.08 | $4.01 | $4.12 | $3.965 | 1,272,522 | 04-16-2024 |
$4.07 | $4.17 | $4.07 | $4.3899 | $4.03 | 1,609,088 | 04-15-2024 |
$4.2 | $4.37 | $4.2 | $4.37 | $4.12 | 1,962,628 | 04-12-2024 |
$4.33 | $4.42 | $4.33 | $4.42 | $4.275 | 950,236 | 04-11-2024 |
$4.35 | $4.39 | $4.35 | $4.44 | $4.205 | 2,135,306 | 04-10-2024 |
News, Short Squeeze, Breakout and More Instantly...
Caribou Biosciences Inc. Company Name:
CRBU Stock Symbol:
NASDAQ Market:
-- Advancing CB-010 ANTLER Phase 1 trial in 2L LBCL; initial dose expansion data to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting -- -- Expanding into autoimmune diseases with IND cleared for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Pha...
NEW YORK, April 27, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigat...
BERKELEY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts have been accepted for poster presentations at the 2024 American Society of Clinical Oncology (ASC...